The Fisher & Paykel Healthcare share price is front and centre today after the company issued upbeat guidance, forecasting first-half revenue of NZ$1.24 billion and net profit after tax (NPAT) of NZ$280 million for the 2027 financial year.
What did Fisher & Paykel Healthcare report?
- Forecast first-half revenue of approximately NZ$1.24 billion, up 14% on the prior corresponding period
- Expected first-half NPAT of around NZ$280 million, up 24% (excluding US tariff refunds)
- Full-year operating revenue guidance: NZ$2.47 billion to $2.57 billion
- Full-year NPAT guidance: NZ$525 million to NZ$565 million (including $23 million in US IEEPA tariff refunds)
- Improvement in gross margin and operating efficiencies anticipated
What else do investors need to know?
Fisher & Paykel Healthcare saw particularly strong demand in its Hospital product group for the start of FY27, driven by adoption of its latest hardware devices and increased consumable sales stemming from changing clinical practices. The company’s positive momentum is also underpinned by continuous improvement activities that are delivering results in gross margin and operating efficiency.
The updated guidance assumes current global tariff rates will remain in place for the financial year. Fisher & Paykel Healthcare’s annual shareholders’ meeting is set for 25 August 2026, offering an opportunity for investors to engage with leadership on strategy and performance.
What did Fisher & Paykel Healthcare management say?
The company’s CEO, Lewis Gradon, said:
We have had a strong start to our first half, particularly in our Hospital product group, as a result of continued strong demand for our latest range of hardware devices and ongoing change in clinical practice driving consumable sales. It is also pleasing to see the progress we are making with our continuous improvement activities and the impact on our gross margin and other operating efficiencies.
What’s next for Fisher & Paykel Healthcare?
Looking ahead, Fisher & Paykel Healthcare plans to keep investing in innovation to support clinicians and adapt to evolving healthcare needs. Management expects continued improvement in gross margin while progressing ongoing projects to sustain the company’s growth momentum.
The current outlook remains subject to changes in global tariffs and foreign exchange conditions, but management remains confident in the strong demand outlook and ability to deliver operating efficiencies.
Fisher & Paykel Healthcare share price snapshot
The Fisher & Paykel Healthcare share price is marginally outperforming the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a gain of around 3%.
The post Fisher & Paykel Healthcare shares: Earnings outlook upgraded for FY27 appeared first on The Motley Fool Australia.
Should you invest $1,000 in Fisher & Paykel Healthcare right now?
Before you buy Fisher & Paykel Healthcare shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Fisher & Paykel Healthcare wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Elevra Lithium share price on watch amid new long-term Mangrove supply deal
- BSP Financial Group earnings: Profit and revenue up for H1 2026
- Ramelius Resources reports profit drop, expands growth plans in FY26 earnings
- Regis Resources delivers record FY26 profit and dividends
- Telstra shares hit fresh 52-week low: What’s next for the ASX 200 telco stock?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.